LP
NVCR icon

LMR Partners’s NovoCure NVCR Stock Holding History

LMR Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,914
Closed -$981K – 1566
2024
Q4 		$981K Buy
+32,914
New +$697K 0.01% 735
2024
Q2 		– Sell
-15,374
Closed -$240K – 1250
2024
Q1 		$240K Buy
+15,374
New +$226K ﹤0.01% 839
2023
Q4 		– Sell
-13,796
Closed -$223K – 1087
2023
Q3 		$223K Buy
+13,796
New +$398K ﹤0.01% 630
2023
Q1 		– Sell
-109,393
Closed -$8.02M – 1132
2022
Q4 		$8.02M Buy
109,393
+2,684
+3% +$202K 0.14% 184
2022
Q3 		$8.11M Sell
106,709
-2,775
-3% -$216K 0.15% 171
2022
Q2 		$7.61M Buy
+109,484
New +$8.25M 0.13% 191
2020
Q3 		– Sell
-18,921
Closed -$1.12M – 576
2020
Q2 		$1.12M Buy
+18,921
New +$1.24M 0.03% 342
2019
Q4 		– Sell
-25,522
Closed -$1.91M – 504
2019
Q3 		$1.91M Buy
+25,522
New +$2.04M 0.09% 107

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

LMR Partners's NVCR Position: Q1 2025 in Review

LMR Partners sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 32,914 shares — an estimated $981K sold.

LMR Partners first reported a position in NVCR in Q3 2019 and held it in 8 quarters. The position peaked at $8.11M in Q3 2022. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • LMR Partners reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 32,914 NovoCure shares in Q1 2025, an estimated $981K.
  • LMR Partners first reported a position in NovoCure in Q3 2019 and held it in 8 quarters.
  • LMR Partners's NovoCure position peaked at $8.11M in Q3 2022.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.